Why Choose Us?

Let China use globally innovative vaccines, and let the world use high-quality vaccines from China!

quanfu quanfu

Strong Corporate Strength

The registered capital is 360 million yuan, the investment in Phase I project is 500 million yuan, the investment in Phase II project is 500 million yuan, and the new investment in Phase III is 2 billion yuan

quanfu quanfu

Products & Services

Committed to the research and development, registration and application, industrial production and sales of innovative vaccines for human use, targeting international standards, and conducting independent innovative research and development.

quanfu quanfu

Scientific Research Capability

Shanghai/Taizhou R&D Center and pilot platform are promoting multiple viral vaccines, bacterial vaccines, conjugate vaccines, recombinant subunit vaccines, and mRNA vaccine pipelines simultaneously.

Product Pipelines

Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio

Quadrivalent Subunit Influenza Vaccine(0.5ml)

Quadrivalent Subunit Influenza Vaccine: the components of the 2018-2019 northern hemisphere tetravalent influenza vaccine recommended by WHO are: A / Michigan / 45 / 2015 (H1N1) pdm09 similar strain, a / Singapore / infimh-16-0019 / 2016 (H3N2) similar strain, B / Colorado / 06 / 2017 (Victoria strain) similar strain and B / Phuket / 3073 / 2013 (Yamagata strain).

More Product Series

News Center

Ab&B Bio Tech CO., LTD. JS invited to attend the China Ukraine Trade Cooperation Seminar

2023-11-28

During the visit, the China Uruguay Trade Cooperation Seminar, organized by the China Council for the Promotion of International Trade, was grandly held in Beijing on the 21st. Uruguayan President Lac

The kickoff meeting for the Phase I clinical trial of freeze-dried human rabies vaccine (human diploid cells) was successfully held

2023-11-27

Recently, the phase I clinical trial kickoff meeting of Ab&B Bio Tech CO., LTD. JS freeze-dried human rabies vaccine (human diploid cells) was successfully held at the research site in Hubei. This cli

Successfully selected as a national open topic!

2023-11-15

Recently, after evaluation by experts from the Drug Evaluation Center of the National Medical Products Administration, Ab&B Bio Tech CO., LTD. JS's "Research on Safety Evaluation of Tetravalent Influe

Have a project?Get a touch!

Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio

Contact

E-mail:info@abbbio.com.cn
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City

Copyright © 2022 Ab&B Bio-Tech CO.,LTD.JS All Rights Reserved.   Powered by:www.300.cn
Search